NCT02967757 - In-market Utilisation of Liraglutide Used for Weight Management in Europe | Biotech Hunter

Enrollment

316

Participants

Timeline

Start Date

December 22, 2016

Primary Completion Date

May 28, 2019

Study Completion Date

May 28, 2019

Conditions

Metabolism and Nutrition DisorderObesity

Interventions

DRUG

liraglutide

Patients will be treated according to routine clinical practice at the discretion of the treating physician. The study will gather data over the course of routine treatment for liraglutide 3.0 mg and liraglutide 1.2 mg/1.8 mg treated patients

Trial Locations (19)

161

Novo Nordisk Investigational Site, Rome

20097

Novo Nordisk Investigational Site, Hamburg

26900

Novo Nordisk Investigational Site, Cremona

28100

Novo Nordisk Investigational Site, Novara

32257

Novo Nordisk Investigational Site, Bünde

45147

Novo Nordisk Investigational Site, Essen

48143

Novo Nordisk Investigational Site, Münster

53100

Novo Nordisk Investigational Site, Siena

55124

Novo Nordisk Investigational Site, Mainz

56126

Novo Nordisk Investigational Site, Pisa

61231

Novo Nordisk Investigational Site, Bad Nauheim

66100

Novo Nordisk Investigational Site, Chieti

67655

Novo Nordisk Investigational Site, Kaiserslautern

81477

Novo Nordisk Investigational Site, München

85100

Novo Nordisk Investigational Site, Potenza

89073

Novo Nordisk Investigational Site, Ulm

95122

Novo Nordisk Investigational Site, Catania

00128

Novo Nordisk Investigational Site, Roma

00168

Novo Nordisk Investigational Site, Rome